In earlier work, a team led by researchers at the Broad Institute and Mass General Brigham discovered a key cell type underlying fibrosis in inflammatory bowel disease (IBD). Now, in a new study published in Nature, the team has characterized the crosstalk between this and other types of cells that leads to fibrosis.
Past research has found that exposure to bright lights and high levels of noise can alter both physiological processes and human behavior. For instance, an elevated or limited exposure to bright lights and noise has been found to influence people’s sleeping patterns, circadian rhythm, mood, metabolism, stress levels and mental performance.
SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ — CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that utilizes artificial intelligence to significantly improve the accuracy and efficiency of bladder cancer detection. This innovative platform enhances traditional urine cytology analysis, providing faster, more precise diagnostics.
Nanoparticles coated with molecular sensors could be used to develop at-home tests for many types of cancer.
Nanomaterial crosses blood-brain barrier, targets harmful inflammation after most common type of stroke
CINCINNATI, Jan. 6, 2026 /PRNewswire/ — LiverRight, the nation’s only National Virtual Clinic for diagnosing and treating Liver Disease in Adults, announces that its telemedicine appointments in 2026 will offer metrics collection using what’s called Contactless Remote Patient Monitoring (RPM).
The B3 GEL System maintains biomechanical separation throughout the essential healing window.
The company will use the money to try to establish its cuffless device as a go-to option for 24-hour blood pressure monitoring in the U.S.
Stereotaxis (NYSE:STXS) has won FDA approval for its robotically navigated MAGiC ablation catheter, offering a minimally invasive option for patients who otherwise might not be eligible for cardiac ablation to treat complex and critical heart rhythm disorders.
W.L. Gore & Associates announced today that the FDA approved its Viabahn Fortegra venous stent, formerly known as Viafort.